Reliably monitor Cytomegalovirus infection
Cytomegalovirus (CMV) is a leading cause of morbidity and mortality in transplant recipients. Severe CMV infection in high risk patients may develop soon after transplantation and without effective treatment, may lead to CMV syndrome, tissue invasive disease, and potential rejection or loss of the graft.1
The COBAS® AmpliPrep/COBAS® TaqMan® CMV Test reliably monitors Cytomegalovirus infection and is proven to provide comparable and reproducible viral load results across different institutions, over several orders of magnitude. It is the first standardised CMV viral load test with CE and FDA approval.2
You can realize the following benefits for your laboratory and clinicians:
The COBAS® AmpliPrep/COBAS® TaqMan® CMV Test demonstrates co-linearity to the WHO international standard, reporting results in IU/mL as recommended by the international consensus guidelines for CMV management in solid organ transplant patients.1,3 It helps bring standardization to sample type (plasma) for testing and delivers results that align across institutions to optimize CMV management.
Roche CMV tests have been central in clinical studies for current treatment regimens and those in development. Extensive studies were conducted in the development of the COBAS® AmpliPrep/COBAS® TaqMan® CMV Test, including clinical trials required to demonstrate clinical utility. The COBAS® AmpliPrep/COBAS® TaqMan® CMV Test is referenced in the International Consensus Guidelines for the Management of CMV in SOT patients (2013) through a multi-centre study conducted by Hirsch, et al.4
The generation and maintenance of an LDT takes time and effort on the part of the laboratory, and places the burden and associated risk for quality compliance and troubleshooting on the laboratory.5,6The COBAS®AmpliPrep/COBAS® TaqMan®CMV Test is validated with ready-to-use reagents, performed on a fully automated platform solution, and includes calibration.7,8